MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Spasticity: Treatment"

  • 2022 International Congress

    Benefit of multiple incobotulinumtoxinA injections for pain reduction in adult patients with limb spasticity: an analysis of pooled data from phase 2 and 3 studies

    J. Wissel, A. Camões-Barbosa2, G. Comes, M. Althaus, A. Scheschonka, D. Simpson (Potsdam, Germany)

    Objective: To assess pain relief after multiple incoA injections in a large sample of pts with limb spasticity-associated pain (SAP) using pooled data from six…
  • 2022 International Congress

    DaxibotulinumtoxinA for Injection in Adults With Upper Limb Spasticity After Stroke or Traumatic Brain Injury: A Randomized Placebo-Controlled Study (JUNIPER)

    A. Patel, M. Munin, Z. Ayyoub, G. Francisco, T. Gross, R. Rubio, J. Kesslak (Lee's Summit, USA)

    Objective: To evaluate the efficacy and safety of 3 doses of DaxibotulinumtoxinA for Injection (DAXI) vs placebo for adults with upper limb spasticity (ULS) after…
  • 2022 International Congress

    Choice of shoulder muscles for the multi-pattern treatment of upper limb spasticity with botulinum neurotoxin injections

    J. Jacinto (Alcabideche, Portugal)

    Objective: To present an experts’ consensus on the use of botulinum neurotoxin (BoNT) injections in the multi-pattern treatment of shoulder spasticity to increase awareness of…
  • 2022 International Congress

    Treating Upper Limb Spasticity With OnabotulinumtoxinA: Subgroup Analysis of US Practice Patterns From the ASPIRE Study

    G. Francisco, W. Feng, M. Munin, K. Ngo, M. Schwartz, M. Sadeghi, A. Zuzek, A. Esquenazi (Houston, USA)

    Objective: To examine onabotulinumtoxinA (onabotA) treatment utilization patterns in the United States (US) for pronated forearm and intrinsic plus hand postures in patients with upper…
  • MDS Virtual Congress 2021

    A phase IV, randomized, double-blind cross-over study comparing the clinical safety, efficacy and duration of abobotulinumtoxinA with onabotulinumtoxinA in adults with upper-limb spasticity: The DIRECTION study

    A. Esquenazi, Z. Ayyoub, M. Verduzco-Gutierrez, P. Maisonobe, J. Otto, A. Patel (Elkins Park, USA)

    Objective: To evaluate the safety and efficacy of abobotulinumtoxinA in comparison to onabotulinumtoxinA when used at optimized doses in approved muscles common to both products’…
  • MDS Virtual Congress 2021

    Gait Improvement in Pegzilarginase-treated Patients With Arginase 1 Deficiency: A Blinded Kinematic Analysis

    N. Foreman, G. Bubb, E. Bradford (Colleyville, USA)

    Objective: To assess the impact of pegzilarginase therapy on gait kinematics in Arginase 1 Deficiency (ARG1-D) patients. Background: High arginine levels in patients with ARG1-D…
  • MDS Virtual Congress 2021

    OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study

    G. Bavikatte, G. Francisco, A. Esquenazi, M. Dimyan, K. Ngo, M. Schwartz, A. Zuzek, W. Jost (Liverpool, United Kingdom)

    Objective: Examine onabotulinumtoxinA utilization in patients with upper limb (UL) and lower limb (LL) spasticity from the Adult Spasticity International Registry (ASPIRE) study to gain…
  • MDS Virtual Congress 2021

    Assessing effectiveness of abobotulinumtoxinA injections for adult lower limb spasticity in routine clinical practice: The ongoing AboLiSh study

    A. Esquenazi, R. Zorowitz, S. Ashford, F. Calvi-Gries, P. Maisonobe, S. Page, J. Jacinto (Elkins Park, USA)

    Objective: The aim of this ongoing observational study is to systematically assess goal attainment over 16 months in patients treated with ≥1 abobotulinumtoxinA (aboBoNT-A) injection(s)…
  • MDS Virtual Congress 2020

    Perceptions of burden of spasticity and treatment satisfaction among post-stroke patients over the course of a botulinum neurotoxin A (BoNT-A) treatment cycle: An ethnographic study

    J. Jacinto, A. Lysandropoulos, A. Fulford-Smith (Estoril, Portugal)

    Objective: To design an ethnographic study following patients over a botulinum toxin type-A (BoNT-A) treatment cycle to inform individualized treatment. Background: The concept of individualized…
  • MDS Virtual Congress 2020

    Evaluating patient out-of-pocket (OOP) expenses using real world utilization data of botulinum toxins

    L. Turner-Stokes, A. Lysandropoulos, S. Wietek, C. Divers (Harrow, United Kingdom)

    Objective: The objective of this study was to evaluate the impact of different brands of botulinum neurotoxin type A (BoNT-A) on OOP patient spending based…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley